In patients who have suspected ET or PMF, the CALR gene will aid in the diagnosis and risk stratification for these patients.
The addition of BloodCenter's CALR test reflects its ongoing commitment to advancing patient care by providing physicians worldwide with leading-edge testing in the area of molecular oncology.
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N Engl Med.
According to an article published in the New England Journal of Medicine in December 2013 by the CeMM team led by Robert Kralovics, patients with CALR mutations suffer from a milder form of the disease than those with the JAK2V617F mutation, including a lower risk of thrombosis and a higher survival rate.
Together, the JAK2 and CALR biomarkers give us the ability to deliver personalized insights regarding diagnosis, prognosis and disease management for patients with myeloprofilerative disorders," said Peer M.
Giulio Superti-Furga, Scientific Director of CeMM, said: "We estimate that up to 3 million people worldwide suffer from myeloproliferative neoplasms, and discovery of the CALR mutation by our CeMM and Medical University of Vienna research teams is a very important finding for the benefit of these patients.
Doug VanOort, the company's Chairman and CEO, said "NeoGenomics is proud to be the first laboratory in the United States to offer CALR testing on a clinical basis.
Maher Albitar, the Company's Chief Medical Officer and Director of Research and Development, commented, "Offering CALR mutation testing compliments our comprehensive testing for patients with MPN.
NeoGenomics' CALR mutation testing is currently available to be ordered with special handling procedures, and will be launched broadly by the end of January.
Mutations in CALR are novel, specific molecular markers detected in the majority of MPN patients without JAK2 and MPL mutations.
The Genomic Landscape of Myeloproliferative Neoplasms: Somatic CALR Mutations in the Majority of JAK2-Wildtype Patients[ LBA-2 ]
Importantly, CALR mutations were identified as a novel biomarker in the vast majority of patients without JAK2 or MPL mutations.